18F-Fluciclovine PET/CT Use in the Evaluation of Epithelial Ovarian Cancer

354Introduction: Epithelial ovarian cancer is associated with high mortality. The optimal treatment of ovarian cancer is surgical debulking with systemic chemotherapy. Standard of care imaging for patients with a pelvic mass suspicious for ovarian malignancy is CT. In up to 50% of cases, CT will fail to localize the true extent of metastatic disease or identify the sub-population likely to benefit from neoadjuvant chemotherapy. Thus, with the currently offered standard of care procedures, patients with ovarian cancer are likely being treated without an accurate estimate of metastatic disease. 18F-Fluciclovine is a synthetic amino acid PET radiotracer that is transported via amino acid transporters such as LAT1, which is upregulated in ovarian cancer cells. 18F-Fluciclovine PET/CT scan is approved for restaging of prostate cancer. The use of 18F-fluciclovine PET/CT scan in ovarian cancer has not been evaluated. Our goal is to characterize 18F-fluciclovine uptake in patients with known ovarian cancer. Methods: Seven female subjects with confirmed primary or recurrent ovarian cancer underwent an 18F-fluciclovine PET/CT scan with dual time-point imaging using two minutes per bed position. Early and delayed images were obtained at 4-22 and 24-42 minutes, respectively. Target and background structures (aorta, L3 vertebral marrow, liver, and bladder) tracer uptake was recorded using max and mean standardized uptake values (SUVs). Target lesions uptake was qualitatively graded by com...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology Clinical Diagnosis: Gynecological Source Type: research

Related Links:

RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This article summarizes the associations between miR-429 and malignant tumors as well as potential action mechanisms. miR-429 has a potential to be used in the future as a biomarker for the diagnosis, treatment and prognosis of certain cancers. PMID: 31884798 [PubMed - as supplied by publisher]
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research
Al-Dayel F, Al-Kuraya KS Abstract Sanger Sequencing and immunohistochemistry was employed to investigate the TERT promoter mutations and TERT protein expression with their association to clinicopathological characteristics in over 2200 samples of Middle Eastern origin from 13 different types of cancers. The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer ...
Source: Genomics - Category: Genetics & Stem Cells Authors: Tags: Genomics Source Type: research
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions Several model systems are now available to characterize the MSC-tumour interplay in the TME. These offer early promise in establishing robust preclinical platforms for the identification of crucial molecular pathways and for the assessment of clinical efficacy of novel drugs to inhibit cancer development and progression. However, selection of the right model for a given study should be shaped on the purpose, and should also consider fixed biological, biochemical, and biophysical parameters according to the specific tumour type. Finally, in order to get reliable and useful results to be translated to the clinic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Eleonora A. Braga1*†, Marina V. Fridman2†, Vitaly I. Loginov1,3, Alexey A. Dmitriev4 and Sergey G. Morozov1 1Institute of General Pathology and Pathophysiology, Moscow, Russia 2Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia 3Research Center of Medical Genetics, Moscow, Russia 4Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia Clear cell renal cell carcinoma (ccRCC) is the third most common urological cancer, and it has the highest mortality rate. The increasing drug resistance of metastatic ccRCC has resulted in the search f...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion In conclusion, genes that display a correlation between DNA methylation and their expression in specific tissues are responsible for significant changes in not only in developmental stages but also in adult tissues. We made this finding by using tissues that are not in developmental stages, but have developed in adults. This can either represent a change that occurs at the developmental stage, or it can be the result of epigenetic changes. This study presents a methodology that can be used by other researchers using omics data combined with different types of NGS data, and provides them with the opportunity to ...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Epithelial Cancer | Liver | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nuclear Medicine | Ovarian Cancer | Ovaries | PET Scan | Prostate Cancer | Study | Urology & Nephrology